


# BETTER EDUCATION ON GLOMERULAR DISEASE: IMPROVING DIAGNOSIS AND TREATMENT OF C3 GLOMERULOPATHY




This program was recorded on November 9, 2022. To obtain CE credit [click here](#).

## References

1. Ahmad SB, Bomback AS. C3 glomerulopathy: Pathogenesis and treatment. *Adv Chronic Kidney Dis*. 2020;27(2):104-110.
2. Avacopan [package insert]. Cincinnati, OH. ChemoCentryx, Inc; October 2021.
3. Avasare RS, Canetta PA, Bomback AS, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. *Clin J Am Soc Nephrol*. 2018;13(3):406-413.
4. Bomback AS, Santoriello D, Avasare RS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. *Kidney Int*. 2018;93(4):977-985.
5. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. *Clin J Am Soc Nephrol*. 2012;7:748-756.
6. Boyle JJ. Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. *Clin Exp Immunol*. 2004;137:529-537.
7. Caravaca-Fontán F, Diaz-Encarnación MM, Lucientes L, et al. Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. *Clin J Am Soc Nephrol*. 2020;15(9):1287-1298.
8. Chadban SJ, Atkins RC. Glomerulonephritis. *Lancet*. 2005;365(9473):1797-1806.
9. Clinicaltrials.gov. Updated April 13, 2022. Accessed November 11, 2022. [https://clinicaltrials.gov/ct2/show/NCT04572854?cond=C3+Glomerulopathy&phase=12&fund=2&prcd\\_s=01%2F01%2F2021&prcd\\_e=12%2F31%2F2024&draw=1&rank=7](https://clinicaltrials.gov/ct2/show/NCT04572854?cond=C3+Glomerulopathy&phase=12&fund=2&prcd_s=01%2F01%2F2021&prcd_e=12%2F31%2F2024&draw=1&rank=7)
10. Clinicaltrials.gov. Updated August 10, 2022. Accessed October 1, 2022. <https://clinicaltrials.gov/ct2/show/results/NCT03832114>
11. Clinicaltrials.gov. Updated August 8, 2022. Accessed November 11, 2022. <https://clinicaltrials.gov/ct2/show/NCT05067127?term=valiant&cond=c3+glomerulopathy&draw=2&rank=1>
12. Clinicaltrials.gov. Updated September 30, 2022. Accessed October 1, 2022. [https://clinicaltrials.gov/ct2/show/NCT03301467?cond=C3+Glomerulopathy&phase=12&fund=2&prcd\\_s=01%2F01%2F2021&prcd\\_e=12%2F31%2F2024&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT03301467?cond=C3+Glomerulopathy&phase=12&fund=2&prcd_s=01%2F01%2F2021&prcd_e=12%2F31%2F2024&draw=2&rank=1)
13. Eculizumab [package insert]. Boston, MA. Alexion Pharmaceuticals, Inc; November 2020.
14. Hari P, Alhasan K, Bagga A, et al. Importance of clinical practice guidelines to practicing pediatric nephrologists and IPNA survey. *Pediatr Nephrol*. 2021;36:3493-3497.
15. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3GN. *J Am Soc Nephrol*. 2012;23(7):1229-1237.
16. Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. *N Engl J Med*. 1998;339(13):888-899.
17. Hsu S, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: A therapeutic role for complement inhibitors? *J Am Soc Nephrol*. 2003;14:S186-S191.
18. Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Mol Immunol*. 2016;71:131-142.

# BETTER EDUCATION ON GLOMERULAR DISEASE: IMPROVING DIAGNOSIS AND TREATMENT OF C3 GLOMERULOPATHY



19. KDIGO Workgroup. KDIGO 2021 Clinical Practice Guideline for Management of Glomerular Diseases. *Kidney Int.* 2021;100(4S):S1-276.
20. Kumar A, Nada R, Ramachandran R, et al. Outcome of C3 glomerulopathy patients: Largest single-centre experience from South Asia. *J Nephrol.* 2020;33:539-550.
21. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. *J Clin Apher.* 2022;135-137.
22. Le Quintrec M, Lapeyraque AL, Lionet A, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. *Am J Kidney Dis.* 2018;72:84-92.
23. Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. *Am J Kidney Dis.* 2005;45:415-421.
24. Marinozzi MC, Chauvet S, Le Quintrec M, et al. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. *Kidney Int.* 2017;92:1232-1241.
25. Master Sankar Raj V, Gordillo R, Chand DH, et al. Overview of C3 glomerulopathy. *Front Pediatr.* 2016;4(May 6):45.
26. McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. *Nephrol Dial Transplant.* 2011;26(2):414-430.
27. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, et al. C3 glomerulopathy: Clinicopathologic features and predictors of outcome. *Clin J Am Soc Nephrol.* 2014;9:46-53.
28. Meri S, Koistinen V, Miettinen A, et al. Activation of the alternative pathway of complement by monoclonal X light chains in membranoproliferative glomerulonephritis. *J Exp Med.* 1992;175:939-950.
29. Rabasco C, Cavero T, Roman E, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. *Kidney Int.* 2015;88(5):1153-1160.
30. Regunathan-Shenk R, Avasare RS, Ahn W, et al. Kidney transplantation in C3 glomerulopathy: A case series. *Am J Kidney Dis.* 2019;73(2):316-323.
31. Riedl M, Thorner P, Licht C. C3 glomerulopathy. *Pediatr Nephrol.* 2017;32(1):43-57.
32. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. *J Med Genet.* 2007;44(3):193-199.
33. Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. *Kidney Int.* 2012;82(4):465-473.
34. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy – understanding a rare complement-driven renal disease. *Nat Rev Nephrol.* 2019;15(3):129-143.
35. Voice of the Patient. Published March 26, 2018. Accessed October 1, 2022. [https://www.kidney.org/sites/default/files/C3G\\_EL-PFDD\\_VoP-Report\\_3-29-18.pdf](https://www.kidney.org/sites/default/files/C3G_EL-PFDD_VoP-Report_3-29-18.pdf)
36. Wetmore JB, Guo H, Liu J, et al. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. *Kidney Int.* 2016;90(4):853-860.
37. Zand L, Lorenz EC, Cosio FG, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. *J Am Soc Nephrol.* 2014;25(5):1110-1117.